Albireo Pharma Inc organizacji Zalecenie średnie
Jaka jest wartość Zalecenie średnie organizacji Albireo Pharma Inc?
Wartość Zalecenie średnie organizacji Albireo Pharma Inc to 1.13
Jaka jest definicja Zalecenie średnie?
Średnia rekomendacja to średnia ocen analityków dla akcji od 1,0 (silny zakup) do 5,0 (silny wzrost).
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
Zalecenie średnie firm w Health Care sektor na NASDAQ w porównaniu do Albireo Pharma Inc
Czym się zajmuję organizacja Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Firmy z zalecenie średnie podobne do Albireo Pharma Inc
- Wartość Zalecenie średnie organizacji Acadia Pharmaceuticals Inc to 1.11
- Wartość Zalecenie średnie organizacji Axonics Inc to 1.11
- Wartość Zalecenie średnie organizacji VICI Properties Inc to 1.11
- Wartość Zalecenie średnie organizacji Aurinia Pharmaceuticals Inc to 1.11
- Wartość Zalecenie średnie organizacji Atreca Inc to 1.11
- Wartość Zalecenie średnie organizacji Natera Inc to 1.11
- Wartość Zalecenie średnie organizacji Albireo Pharma Inc to 1.13
- Wartość Zalecenie średnie organizacji AdaptHealth Corp to 1.14
- Wartość Zalecenie średnie organizacji Nomad Foods to 1.14
- Wartość Zalecenie średnie organizacji Alibaba Ltd to 1.14
- Wartość Zalecenie średnie organizacji Phillips 66 to 1.14
- Wartość Zalecenie średnie organizacji Aldeyra Therapeutics Inc to 1.14
- Wartość Zalecenie średnie organizacji Compugen Ltd to 1.14